Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Pick the Right Toothbrush for Your Teeth - 2Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 3A Couple of Modest Guitars for 2024
- 4The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- 5Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- Top 15 Web-based Entertainment Stages for Individual Marking
- Aspirin can prevent a serious pregnancy complication — but too few women get it, new report suggests
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Fundamental Archives for Beginning Your Business
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- vote in favor of Your #1 kind of climate
- 6 Tire Brands Reasonable for Seniors
- Tech for Learning: Online Courses and Instructive Apparatuses
- If you want a true taste of Italian paradise, head to Favignana
